Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer(Johns Hopkins University), John A. Thompson(Fred Hutch Cancer Center), Bianca Santomasso(Georgetown University), Jennifer Holter Chakrabarty(Georgetown University), Aung Naing(The University of Texas MD Anderson Cancer Center), David F. McDermott(Beth Israel Deaconess Medical Center), Natasha B. Leighl(Princess Margaret Cancer Centre), Jennifer M. Gardner(Seattle Cancer Care Alliance), Ian Chau(Royal Marsden NHS Foundation Trust), Bryan J. Schneider(Georgetown University), Carole Seigel(Georgetown University), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Christina Lacchetti(Washington Hospital), Jeffrey M. Caterino(Georgetown University), Jennifer S. Mammen(Johns Hopkins Medicine), Jeffrey S. Weber(NYU Langone Health), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Michael B. Atkins(Georgetown University), Jedd D. Wolchok(Cornell University), Kelly Brassil(Georgetown University), María E. Suarez‐Almazor(The University of Texas MD Anderson Cancer Center), Tanyanika Phillips(Georgetown University), Sigrun Hallmeyer(Georgetown University), Cristina Reichner(Georgetown University), Laura Porter(Georgetown University), Marc S. Ernstoff(National Cancer Institute), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Alexander I. Spira(Virginia Cancer Specialists), Pamela Ginex(Georgetown University)
Cited by 3,688
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k